BS01
Retinitis Pigmentosa
Key Facts
About Bionic Sight
Bionic Sight is a clinical-stage biotech pioneering a novel vision restoration platform that merges optogenetic gene therapy with neural code deciphering. Its lead program, BS01, is in Phase 1/2 trials for retinitis pigmentosa and geographic atrophy, with the RP program FDA Fast Tracked and preparing for Phase 3. Founded by MacArthur Award-winning neuroscientist Dr. Sheila Nirenberg, the company leverages world-class expertise in neural decoding and AAV gene therapy to address a significant unmet need in advanced blindness. Bionic Sight represents a unique, platform-based approach with potential applications across multiple retinal degenerative diseases.
View full company profileAbout Bionic Sight
Bionic Sight is a clinical-stage biotech pioneering a novel vision restoration platform that merges optogenetic gene therapy with neural code deciphering. Its lead program, BS01, is in Phase 1/2 trials for retinitis pigmentosa and geographic atrophy, with the RP program FDA Fast Tracked and preparing for Phase 3. Founded by MacArthur Award-winning neuroscientist Dr. Sheila Nirenberg, the company leverages world-class expertise in neural decoding and AAV gene therapy to address a significant unmet need in advanced blindness. Bionic Sight represents a unique, platform-based approach with potential applications across multiple retinal degenerative diseases.
View full company profileTherapeutic Areas
Other Retinitis Pigmentosa Drugs
| Drug | Company | Phase |
|---|---|---|
| Endogena Therapeutics Program | Centenara Labs | Phase 1b/2a |
| jCell | jCyte | Phase 3 |
| EA-2353 | Endogena Therapeutics | Phase I/IIa |
| NPI-001 | Nacuity Pharmaceuticals | Phase 2/3 |
| MCO-010 | Nanoscope Therapeutics | Phase 2/3 |
| RTx-015 | Ray Therapeutics | Phase 1 |
| OCU400 | Ocugen | Phase 3 |
| ADX-2191 | Aldeyra Therapeutics | Phase 2 |